Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $44.00 Analyst target: $54.22 Upside: 23.23%
Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform. The company combines proprietary technologies with a distinguished scientific team to create a diverse pipeline of innovative therapeutics aimed at addressing significant unmet medical needs across various therapeutic areas. With a strong emphasis on research and development, Septerna is poised for substantial growth, presenting institutional investors with an attractive opportunity in the rapidly evolving biopharmaceutical landscape.
See the full interactive analysis & chart →Informational only — not investment advice.